pneumon
lead
caus
death
associ
use
epiderm
growth
factor
receptor
egfr
tyrosin
kinas
inhibitor
egfrtki
nonsmal
cell
lung
cancer
nsclc
howev
risk
factor
mechan
underli
toxic
elucid
tumor
necrosi
factor
tnf
report
transactiv
egfr
pulmonari
epitheli
cell
henc
aim
test
hypothesi
egfr
tyrosin
kinas
activ
regul
tnfmediat
bronchial
epitheli
cell
surviv
inhibit
egfr
activ
increas
tnfinduc
lung
epitheli
cell
apoptosi
use
surfact
protein
c
spc
tnf
transgen
tg
mice
overexpress
tnf
lung
model
gefitinib
egfrtki
enhanc
lung
epitheli
cell
apoptosi
lymphocyt
inflamm
indic
egfr
tyrosin
kinas
prevent
tnfinduc
lung
injuri
furthermor
significantli
upregul
gefitinib
spctnf
tg
mice
activ
observ
indic
pathway
involv
lung
epitheli
cell
apoptosi
moreov
lung
epitheli
cell
tnf
stimul
egfr
transactiv
via
enzym
manner
requir
heparin
bind
hb
egf
transform
growth
factor
tgf
novel
find
signific
implic
understand
role
egfr
maintain
human
bronchial
epitheli
cell
homeostasi
nsclc
treatment
epiderm
growth
factor
receptor
egfr
tyrosin
kinas
inhibitor
tki
given
standard
therapi
nonsmal
cell
lung
cancer
nsclc
patient
carri
activ
mutat
egfr
gene
egfrtki
gefitinib
administ
nsclc
patient
carri
activ
egfr
mutat
eg
delet
exon
exon
significantli
improv
respons
surviv
furthermor
egfr
mutat
predominantli
found
patient
eastasian
origin
howev
although
egfrtki
treatment
signific
effect
respons
prognosi
studi
report
patient
treat
egfrtki
experi
sever
advers
event
treatment
discontinu
patient
unmanag
sever
advers
event
diarrhea
rash
frequent
advers
effect
tabl
cytokin
mrna
express
profil
wildtyp
wt
vs
surfact
protein
ctumor
necrosi
factor
transgen
spctnf
tg
mous
lung
tissu
lung
mrna
transcript
wt
spctnf
tg
mice
quantifi
realtim
pcr
normal
gapdh
data
repres
rel
control
valu
mean
sem
n
signific
valu
indic
boldfac
gefitinib
mgkg
oral
administ
daili
wild
type
wt
spctnf
tg
mice
day
wild
type
wt
mice
signific
patholog
chang
observ
figur
spctnf
tg
mice
administr
gefitinib
result
sever
lymphocyt
infiltr
alveolar
septa
mice
also
develop
thicker
alveolar
septa
nonadminist
mice
figur
day
administr
also
death
relat
gefitinib
administr
moreov
chang
bodi
weight
either
wt
spctnf
tg
mice
figur
determin
inflammatori
cytokin
mediat
lymphocyt
infiltr
spctnf
tg
mice
realtim
rt
pcr
perform
tabl
wt
mice
although
mrna
level
proinflammatori
cytokin
significantli
increas
inflamm
lung
injuri
observ
suggest
mainten
balanc
antiinflammatori
cytokin
unknown
mechan
mrna
level
found
significantli
increas
gefitinib
administr
taken
togeth
result
suggest
treatment
egfrtki
might
caus
lung
inflamm
spctnf
tg
mice
overexpress
tnf
lung
gefitinib
enhanc
lymphocyt
infiltr
caus
lung
tissu
inflamm
lung
tissu
section
wild
type
wt
mice
b
surfact
protein
ctumor
necrosi
factor
spctnf
transgen
tg
mice
stain
hematoxylin
eosin
imag
obtain
magnif
upper
lower
row
respect
c
bodi
weight
chang
shown
wt
spctnf
tg
mice
day
daili
oral
treatment
tween
control
gefitinb
mgkg
wt
spctnf
tg
mice
use
studi
week
old
scale
bar
repres
magnif
respect
data
figur
repres
mean
bodi
weight
sem
p
student
ttest
figur
gefitinib
enhanc
lymphocyt
infiltr
caus
lung
tissu
inflamm
lung
tissu
section
wild
type
wt
mice
b
surfact
protein
ctumor
necrosi
factor
spctnf
transgen
tg
mice
stain
hematoxylin
eosin
imag
obtain
magnif
upper
lower
row
respect
c
bodi
weight
chang
shown
wt
spctnf
tg
mice
day
daili
oral
treatment
tween
control
gefitinb
mgkg
wt
spctnf
tg
mice
use
studi
week
old
scale
bar
repres
magnif
respect
data
figur
repres
mean
bodi
weight
sem
p
student
ttest
evalu
extent
gefitinibinduc
inflamm
mous
lung
use
indocyanin
green
icg
load
liposom
label
sialyl
lewi
x
slx
surfac
slxlipoicg
slxlipoicg
could
accumul
region
inflamm
tumor
owe
interact
slx
eselectin
enhanc
eselectin
express
inflammatori
cytokin
tnf
vascular
endotheli
cell
wt
spctnf
tg
mice
measur
wholelung
fluoresc
ex
vivo
use
clairvivo
opt
fluoresc
imag
system
observ
slight
accumul
icgload
liposom
whole
lung
spctnf
tg
mice
treat
gefitinib
compar
whole
lung
wt
mice
furthermor
day
gefitinib
administr
accumul
liposom
enhanc
wholelung
sampl
taken
spctnf
tg
mice
howev
enhanc
liposom
accumul
gefitinib
treatment
wt
mice
figur
b
result
suggest
egfr
tyrosin
kinas
activ
protect
mice
tnfinduc
lung
inflamm
mice
model
interact
slx
eselectin
enhanc
eselectin
express
inflammatori
cytokin
tnf
vascular
endotheli
cell
wt
spctnf
tg
mice
measur
wholelung
fluoresc
ex
vivo
use
clairvivo
opt
fluoresc
imag
system
observ
slight
accumul
icgload
liposom
whole
lung
spctnf
tg
mice
treat
gefitinib
compar
whole
lung
wt
mice
furthermor
day
gefitinib
administr
accumul
liposom
enhanc
wholelung
sampl
taken
spctnf
tg
mice
howev
enhanc
liposom
accumul
gefitinib
treatment
wt
mice
figur
b
result
suggest
egfr
tyrosin
kinas
activ
protect
mice
tnfinduc
lung
inflamm
mice
model
figur
gefitinib
enhanc
lung
inflamm
surfact
protein
ctumor
necrosi
factor
spctnf
transgen
tg
mice
indocyanin
green
icg
load
liposom
carri
sialyl
lewi
x
use
detect
region
inflamm
whole
lung
wildtyp
wt
b
spctnf
tg
mice
daili
gefitinib
mgkg
treatment
day
imag
captur
use
clairvivo
opt
vivo
imag
system
shimadzu
kyoto
japan
tnf
pleiotrop
cytokin
activ
antiand
proapoptot
signal
pathway
cell
surviv
determin
balanc
two
pathway
therefor
detect
cell
undergo
apoptosi
situ
oligolig
isol
wt
spctnf
tg
mice
gefitinib
administr
figur
c
gefitinib
administr
significantli
enhanc
apoptosi
lung
epitheli
cell
spctnf
tg
mice
wt
mice
figur
egfr
figur
gefitinib
enhanc
lung
inflamm
surfact
protein
ctumor
necrosi
factor
spctnf
transgen
tg
mice
indocyanin
green
icg
load
liposom
carri
sialyl
lewi
x
use
detect
region
inflamm
whole
lung
wildtyp
wt
b
spctnf
tg
mice
daili
gefitinib
mgkg
treatment
day
imag
captur
use
clairvivo
opt
vivo
imag
system
shimadzu
kyoto
japan
tnf
pleiotrop
cytokin
activ
antiand
proapoptot
signal
pathway
cell
surviv
determin
balanc
two
pathway
therefor
detect
cell
undergo
apoptosi
situ
oligolig
isol
wt
spctnf
tg
mice
gefitinib
administr
figur
c
gefitinib
administr
significantli
enhanc
apoptosi
lung
epitheli
cell
spctnf
tg
mice
wt
mice
figur
egfr
phosphoryl
pegfr
significantli
increas
spctnf
tg
mice
compar
wt
mice
figur
f
moreov
egfr
tyrosin
kinas
activ
indic
egfr
phosphoryl
significantli
inhibit
spctnf
tg
mice
gefitinib
administr
figur
g
activ
phosphoryl
downstream
signal
akt
also
decreas
spctnf
tg
mice
figur
antiapoptot
respons
mediat
akt
raf
els
activ
phosphoryl
lead
apoptosi
therefor
apoptosi
spctnf
tg
mice
may
induc
mapk
pathway
via
map
kinas
kinas
mkk
addit
inhibit
akt
activ
gefitinib
exposur
figur
determin
mechan
egfr
transactiv
tnf
exposur
lung
epitheli
cell
cell
employ
first
cell
expos
tnf
ngml
min
stimul
egfr
phosphoryl
initi
min
tnf
exposur
figur
moreov
egfr
phosphoryl
enhanc
tnf
dosedepend
matter
figur
tnfinduc
egfr
phosphoryl
inhibit
gefitinib
suggest
necess
egfr
tyrosin
kinas
activ
regard
figur
transfect
small
interf
rna
sirna
egfr
cell
led
decreas
egfr
express
attenu
tnfinduc
egfr
phosphoryl
figur
therefor
tnfinduc
egfr
phosphoryl
requir
express
activ
egfr
interestingli
expos
cell
simultan
tnf
gefitinib
enhanc
tnfinduc
apoptosi
figur
f
result
suggest
egfr
phosphoryl
tnf
inhibit
tnfinduc
apoptosi
figur
f
moreov
egfr
tyrosin
kinas
activ
indic
egfr
phosphoryl
significantli
inhibit
spctnf
tg
mice
gefitinib
administr
figur
g
activ
phosphoryl
downstream
signal
akt
also
decreas
spctnf
tg
mice
figur
antiapoptot
respons
mediat
akt
raf
els
activ
phosphoryl
lead
apoptosi
therefor
apoptosi
spctnf
tg
mice
may
induc
mapk
pathway
via
map
kinas
kinas
mkk
addit
inhibit
akt
activ
gefitinib
exposur
figur
determin
mechan
egfr
transactiv
tnf
exposur
lung
epitheli
cell
cell
employ
first
cell
expos
tnf
ngml
min
stimul
egfr
phosphoryl
initi
min
tnf
exposur
figur
moreov
egfr
phosphoryl
enhanc
tnf
dosedepend
matter
figur
tnfinduc
egfr
phosphoryl
inhibit
gefitinib
suggest
necess
egfr
tyrosin
kinas
activ
regard
figur
transfect
small
interf
rna
sirna
egfr
cell
led
decreas
egfr
express
attenu
tnfinduc
egfr
phosphoryl
figur
therefor
tnfinduc
egfr
phosphoryl
requir
express
activ
egfr
interestingli
expos
cell
simultan
tnf
gefitinib
enhanc
tnfinduc
apoptosi
figur
f
result
suggest
egfr
phosphoryl
tnf
inhibit
tnfinduc
apoptosi
tace
facilit
shed
egfr
ligand
avail
bind
stimul
egfr
process
call
autocrin
loop
cell
tace
inhibitor
suppress
tnfinduc
egfr
phosphoryl
egfstimul
figur
furthermor
enhanc
tnfinduc
apoptosi
significantli
figur
c
suggest
tace
mediat
egfr
phosphoryl
lead
cell
surviv
upon
tnf
exposur
major
downstream
signal
egfr
includ
raserk
pathway
tnf
transactiv
egfr
shed
mainli
two
egfr
ligand
determin
signal
molecul
downstream
egfr
regul
cell
surviv
presenc
tnf
use
wortmannin
inhibit
akt
respect
wortmannin
alon
induc
apoptosi
cell
wortmannin
significantli
enhanc
tnfinduc
apoptosi
affect
tnfinduc
apoptosi
figur
e
therefor
pathway
may
contribut
cell
surviv
via
tnfinduc
egfr
transactiv
although
would
difficult
recapitul
spctnf
tg
mous
model
use
cell
specul
signal
contribut
tnfinduc
apoptosi
cetuximab
egfrneutr
antibodi
bind
egfr
downregul
ligandinduc
egfr
phosphoryl
verifi
involv
egfr
ligand
tnfinduc
egfr
transactiv
use
neutral
antibodi
egfr
therefor
tnfinduc
egfr
phosphoryl
inhibit
cetuximab
indic
egfr
ligand
contribut
egfr
transactiv
tnf
figur
identifi
egfr
ligand
involv
tnfinduc
egfr
phosphoryl
neutral
antibodi
employ
shown
figur
egfrtransactiv
tnf
attenu
treatment
neutral
antibodi
hbegf
furthermor
combin
neutral
antibodi
hbegf
exhibit
remark
inhibit
egfr
phosphoryl
presenc
tnf
figur
measur
express
hbegf
cultur
supernat
elisa
perform
hbegf
express
cultur
supernat
increas
upon
tnf
exposur
howev
presenc
reduc
express
egfrligand
figur
e
moreov
knockdown
tace
use
sirna
figur
reduc
amount
hbegf
cultur
supernat
figur
h
result
indic
express
hbegf
cultur
supernat
regul
tace
ligand
involv
tnfinduc
transactiv
cell
taken
togeth
lung
epitheli
cell
protect
tnfinduc
apoptosi
egfr
transactiv
via
autocrin
loop
egfr
ligand
hbegf
cleav
tace
studi
perform
verifi
hypothesi
egfrtki
induc
pneumon
block
egfr
transactiv
tnf
mechan
egfrtkiinduc
pneumon
complet
elucid
howev
studi
provid
evid
egfr
tyrosin
kinas
activ
prevent
lung
injuri
tnfenrich
environ
furthermor
found
lung
epitheli
cell
tace
requir
tnfinduc
egfr
activ
target
egfr
transactiv
find
show
transactiv
egfr
prevent
tnfinduc
lung
epitheli
cell
apoptosi
tnfinduc
egfr
phosphoryl
regul
critic
physiolog
respons
acut
lung
injuri
airway
inflamm
character
releas
proinflammatori
cytokin
tnf
induc
excess
egfr
signal
high
amount
egfr
ligand
amphiregulin
secret
bronchial
epitheli
cell
result
activ
egfr
autocrin
loop
lead
increas
mucu
product
goblet
cell
therefor
inhibit
egfr
tyrosin
kinas
activ
may
benefici
treatment
hypersecretori
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
bronchiectasi
convers
egfrligand
egf
regul
lung
epitheli
cell
repair
vitro
vivo
egfr
overexpress
activ
respons
lung
epitheli
injuri
play
import
role
lung
epitheli
repair
increas
amount
egfr
observ
bleomycininjur
lung
addit
identifi
bronchoalveolar
lavag
fluid
patient
acut
lung
injuri
taken
togeth
express
egfr
egfrligand
egfr
tyrosin
kinas
activ
protect
lung
epitheli
cell
apoptosi
enhanc
recoveri
lung
inflamm
injuri
howev
studi
requir
discov
role
egfr
ligand
inflammatori
lung
diseas
studi
egfr
tyrosin
kinas
transactiv
tnf
spctnf
tg
mice
inhibit
egfr
tyrosin
kinas
gefitinib
increas
tnfinduc
apoptosi
epitheli
cell
significantli
enhanc
lung
injuri
result
studi
consist
previou
report
show
activ
egfr
erbb
famili
member
protect
colon
epitheli
cell
tnfinduc
apoptosi
understand
develop
pneumon
whole
lung
essenti
evalu
lung
inflamm
egfrtki
gefitinib
administr
ex
vivo
region
inflamm
arthriti
tumor
vascular
endotheli
cell
activ
inflammatori
cytokin
tnf
leukocyt
roll
vascular
endotheli
cell
bind
eselectin
vascular
endotheli
cell
surfac
leukocyt
infiltr
vascular
endothelium
migrat
accumul
inflammatori
region
sugar
chain
sialyl
lewi
x
slx
well
character
eselectin
ligand
express
surfac
leukocyt
therefor
slxliposom
primarili
target
eselectin
activ
endotheli
cell
deliv
accumul
icg
content
region
inflamm
within
tumor
therefor
employ
slxlipoicg
evalu
lung
tissu
inflamm
administr
gefitinib
wt
spctnf
tg
mice
basal
accumul
slxlipoicg
spctnf
tg
mice
higher
wt
mice
furthermor
gefitinib
administr
accumul
slxlipoicg
enhanc
spctnf
tg
mice
wt
mice
result
indic
gefitinib
remark
enhanc
tnfinduc
lung
inflamm
spctnf
tg
mice
base
result
significantli
increas
cytokin
gefitinib
treatment
spctnf
tg
mice
appear
act
primarili
nonhematopoiet
cell
endotheli
cell
epitheli
cell
fibroblast
increas
express
link
inflammatori
diseas
asthma
cystic
fibrosi
copd
airway
well
inflammatori
bowel
diseas
appear
play
import
protect
role
infect
iyoda
et
al
report
stimul
phosphoryl
mapk
enhanc
express
cytokin
monocyt
chemoattract
protein
mcp
macrophag
inflammatori
protein
mip
cultur
mous
mesangi
cell
spctnf
tg
mice
gefitinib
treatment
led
increas
phosphoryl
mapk
suggest
may
stimul
mapk
activ
induc
lung
epitheli
cell
apoptosi
metaanalysi
trial
egfr
tki
treatment
lung
cancer
patient
reveal
pneumon
common
caus
death
relat
egfr
tki
toxic
previou
clinic
studi
identifi
risk
factor
egfr
tkiinduc
pneumon
includ
old
age
smoke
histori
preexist
interstiti
lung
diseas
poor
perform
statu
exampl
higher
plasma
concentr
tnf
measur
older
group
younger
group
smoke
may
influenc
tnfmediat
system
inflamm
copd
interstiti
pneumon
furthermor
poorperform
statu
cachexia
associ
cytokin
tnf
well
known
taken
togeth
risk
factor
associ
tnfenrich
lung
condit
therefor
case
egfr
tkiinduc
pneumon
egfr
tyrosin
kinas
activ
may
requir
maintain
homeostasi
tnfrich
lung
environ
chronic
inflamm
present
summari
abl
elucid
molecular
mechan
relat
egfrtkiinduc
lung
injuri
use
spctnf
tg
mice
egfr
activ
prevent
tnfinduc
apoptosi
sever
inflamm
upregul
cytokin
may
involv
furthermor
lung
epitheli
cell
found
tnf
activ
egfr
phosphoryl
stimul
hbegf
via
tace
activ
egfr
transactiv
tnf
regul
cell
surviv
taken
togeth
find
provid
biolog
mechan
underli
egfrtkiinduc
lung
injuri
therefor
find
suggest
caution
taken
prior
administr
egfrtki
nsclc
case
associ
high
level
tnf
inflamm
studi
potenti
limit
effect
report
base
spctnf
tg
mice
highli
express
tnf
whole
lung
howev
exclud
effect
cytokin
signal
transduct
associ
lung
fibrosi
would
address
futur
research
pretreat
min
treat
tnf
ngml
variou
durat
supernat
analyz
elisa
accord
manufactur
recommend
signific
differ
two
group
determin
pair
student
ttest
statist
signific
set
p
experi
repeat
least
three
time
separ
occas
